<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03282227</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2017-001</org_study_id>
    <nct_id>NCT03282227</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine</brief_title>
  <acronym>ADAM</acronym>
  <official_title>A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, twelve-month safety study. There is a screening period followed by a
      run-in period to record migraine activity. Qualified subjects will receive study medication
      for up to twelve months for the treatment of multiple migraine attacks. Using the eDiary to
      confirm they are experiencing a qualified migraine, subjects will self-administer the patches
      and respond to questions in the eDiary post treatment administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, twelve-month safety study. There is a screening period followed by a
      run-in period (14 to 21 days) to determine eligibility for treatment with study medication
      based on daily eDiary data collection. Qualified subjects will receive study medication on
      Day 1 for up to twelve months for the treatment of migraine headaches. Migraines will be
      treated with a single dose, consisting of two patches, but subjects can treat multiple
      migraine attacks throughout the 12 months. Using the eDiary to confirm they are experiencing
      a qualified migraine, subjects will self-administer the patches and continue to respond to
      questions in the eDiary for 48 hours post treatment administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Actual">May 17, 2019</completion_date>
  <primary_completion_date type="Actual">May 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single dose, open-label treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety as measured by incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Long-term safety as measured by incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with pain freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with pain freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with most bothersome symptom freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with freedom from most bothersome symptom other than pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with pain relief</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with pain relief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with nausea freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with nausea freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with photophobia freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with photophobia freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with phonophobia freedom</measure>
    <time_frame>30 minutes; 2, 12, 24, 48 hours</time_frame>
    <description>Proportion of subjects with phonophobia freedom</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>M207 Microneedle System 3.8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M207 Microneedle System</intervention_name>
    <description>M207 Microneedle System 3.8 mg</description>
    <arm_group_label>M207 Microneedle System 3.8 mg</arm_group_label>
    <other_name>ZP-Zolmitriptan Intracutaneous Microneedle System</other_name>
    <other_name>ADAM-Zolmitriptan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Women or men 18 to 75 years of age

          2. Greater than 1 year history of episodic, migraine (with or without aura) with onset
             prior to 50 years of age.

          3. Migraine history during the prior 6 months must include:

               1. at least 2 migraines per month

               2. no more than 8 migraines per month

               3. no more than 15 headache days per month

          4. Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy
             and use an acceptable double-barrier method of birth control during the trial.

          5. Willing and able to treat a minimum of 2 migraines per month with study medication and
             consistently complete eDiary for up to 12 months.

        Main Exclusion Criteria:

          1. Contraindication to triptans

          2. Use of SSRIs (drugs like Prozac®) or SNRIs (drugs like Effexor®) or anti-coagulants
             (drugs like Coumadin®)

          3. Known allergy or sensitivity to zolmitriptan or its derivatives or formulations

          4. Known allergy or sensitivity to adhesives and/or titanium

          5. Women who are pregnant, breast-feeding or plan a pregnancy during this study

          6. Three or more of the following cardiovascular risk factors:

               -  Current tobacco use

               -  Hypertension or receiving anti-hypertensive medication for hypertension

               -  Hyperlipidemia or on prescribed anti-cholesterol treatment

               -  Family history of premature coronary artery disease

               -  Diabetes mellitus

          7. History or current abuse or dependence on alcohol or drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Kellerman, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zosano Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown L.A. Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma Associates of Santa Clara Valley Research Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy Asthma Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmony Medical Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Headache and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research LLC</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303-3041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest Research</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Medical Group PMG Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillestol Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Care Associates/Radiant Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Neurology Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>May 19, 2019</last_update_submitted>
  <last_update_submitted_qc>May 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>migraine headache</keyword>
  <keyword>acute migraine</keyword>
  <keyword>acute migraine headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxazolidinones</mesh_term>
    <mesh_term>Zolmitriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 20, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

